Auranofin

Auranofin
Clinical data
Trade names	Ridaura
AHFS/Drugs.com	Consumer Drug Information
MedlinePlus	a685038
Pregnancy; category	AU: B3; ;
Routes of; administration	Oral
ATC code	M01CB03 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); UK: POM (Prescription only); US: WARNINGRx-only;
Pharmacokinetic data
Bioavailability	40%
Protein binding	60%
Metabolism	Plasma membrane of the cell removes the acetyl groups of the glucose moiety.
Elimination half-life	21-31 days
Excretion	Urine (60%), faeces
Identifiers
	IUPAC name Gold(+1) cation; 3,4,5-triacetyloxy-6- (acetyloxymethyl) oxane-2-thiolate; triethylphosphanium;
CAS Number	34031-32-8 ;
PubChem CID	6333901;
DrugBank	DB00995 ;
ChemSpider	21242895 ;
UNII	3H04W2810V;
KEGG	D00237 ;
ChEBI	CHEBI:2922 ;
ChEMBL	ChEMBL1366 ;
CompTox Dashboard (EPA)	DTXSID4020115 ;
ECHA InfoCard	100.047.077
Chemical and physical data
Formula	C20H34AuO9PS0
Molar mass	678.48 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCP(=[Au]S[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)COC(=O)C)OC(=O)C)OC(=O)C)OC(=O)C)(CC)CC;
	InChI InChI=1S/C14H20O9S.C6H15P.Au/c1-6(15)19-5-10-11(20-7(2)16)12(21-8(3)17)13(14(24)23-10)22-9(4)18;1-4-7(5-2)6-3;/h10-14,24H,5H2,1-4H3;4-6H2,1-3H3;/q;;+1/p-1/t10-,11-,12+,13-,14+;;/m1../s1 ; Key:AUJRCFUBUPVWSZ-XTZHGVARSA-M ;
	(what is this?) (verify)

Auranofin is an orally administered gold salt classified by the World Health Organization as an antirheumatic agent. It has the brand name Ridaura. Along with sodium aurothiomalate it is one of only two gold compounds currently employed in modern medicine.^[4]

^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 Oct 2023.
^ ^a ^b ^c ^d Kean WF, Hart L, Buchanan WW (May 1997). "Auranofin". British Journal of Rheumatology. 36 (5): 560–572. doi:10.1093/rheumatology/36.5.560. PMID 9189058.
^ ^a ^b ^c ^d "Ridaura (auranofin) dosing, indications, interactions, adverse effects, and more". Medscape Reference. WebMD. Retrieved 13 March 2014.
^ Kean WF, Kean IR (June 2008). "Clinical pharmacology of gold". Inflammopharmacology. 16 (3): 112–25. doi:10.1007/s10787-007-0021-x. PMID 18523733. S2CID 808858.